Impact of Asthma Exacerbations and Asthma Triggers on Asthma-related Quality of Life in Patients with Severe or Difficult-to-Treat Asthma

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 5, 2014, Pages 544-552.e2

  Luskin, Allan T ^a   Chipps, Bradley E ^b   Rasouliyan, Lawrence ^c   Miller, Dave P ^c   Haselkorn, Tmirah ^d   Dorenbaum, Alejandro ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Capital Allergy and Respiratory Disease Center   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d GENENTECH INC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic triggers; Difficult to treat asthma; Quality of life; Severe asthma

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BODY MASS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; EMOTIONAL STRESS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POLLEN; QUALITY OF LIFE; QUESTIONNAIRE; RHINITIS; SCORING SYSTEM; CLINICAL TRIAL; COHORT ANALYSIS; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGY; SELF REPORT; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ASTHMA; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84926171978     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.02.011     Document Type: Article

References (35)

1. Bahadori K., Doyle-Waters M.M., Marra C., Fitzgerald J.M. Economic burden of asthma: a systematic review. BMC Pulm Med 2009, 9:24.
2. Accordini S., Bugiani M., Arossa W., Gerzeli S., Marinoni A., Olivieri M., et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006, 141:189-198.
3. Zeiger R.S., Hay J.W., Contreras R., Chen W., Quinn V.P., Seal B., et al. Asthma costs and utilization in a managed care organization. JAllergy Clin Immunol 2008, 121:885-892.
4. Breekveldt-Postma N.S., Erkens J.A., Aalbers R., van der Ven M.J., Lammers J.W., Herings R.M. Extent of uncontrolled disease and associated medical costs in severe asthma: a PHARMO study. Curr Med Res Opin 2008, 24:975-983.
5. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13.
6. Peters S.P., Jones C.A., Haselkorn T., Mink D.R., Valacer D.J., Weiss S.T. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. JAllergy Clin Immunol 2007, 119:1454-1461.
7. Haselkorn T., Fish J.E., Zeiger R.S., Szefler S.J., Miller D.P., Chipps B.E., et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. JAllergy Clin Immunol 2009, 124:895-902.
8. Miller M.K., Lee J.H., Miller D.P., Wenzel S.E. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007, 101:481-489.
9. Haldar P., Pavord I.D., Shaw D.E., Berry M.A., Thomas M., Brightling C.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
10. Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. NEngl J Med 1997, 337:1405-1411.
11. Moore W.C., Bleecker E.R., Curran-Everett D., Erzurum S.C., Ameredes B.T., Bacharier L., et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. JAllergy Clin Immunol 2007, 119:405-413.
12. Akinbami L.J., Moorman J.E., Bailey C., Zahran H.S., King M., Johnson C.A., et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012, (94):1-8.
13. Busse P.J., Cohn R.D., Salo P.M., Zeldin D.C. Characteristics of allergic sensitization among asthmatic adults older than 55 years: results from the National Health and Nutrition Examination Survey, 2005-2006. Ann Allergy Asthma Immunol 2013, 110:247-252.
14. Lloyd A., Price D., Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007, 16:22-27.
15. Peterson M.G., Gaeta T.J., Birkhahn R.H., Fernandez J.L., Mancuso C.A. History of symptom triggers in patients presenting to the emergency department for asthma. JAsthma 2012, 49:629-636.
16. Dolan C.M., Fraher K.E., Bleecker E.R., Borish L., Chipps B., Hayden M.L., et al. Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004, 92:32-39.
17. Juniper E.F., Guyatt G.H., Cox F.M., Ferrie P.J., King D.R. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999, 14:32-38.
18. Zeiger R.S., Yegin A., Simons F.E., Haselkorn T., Rasouliyan L., Szefler S.J., et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012, 108:81-87.
19. Covar R.A., Szefler S.J., Zeiger R.S., Sorkness C.A., Moss M., Mauger D.T., et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. JAllergy Clin Immunol 2008, 122:741-747.
20. Haselkorn T., Fish J.E., Chipps B.E., Miller D.P., Chen H., Weiss S.T. Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir Med 2009, 103:274-283.
21. Chipps B.E., Zeiger R.S., Borish L., Wenzel S.E., Yegin A., Hayden M.L., et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. JAllergy Clin Immunol 2012, 130:332-342.e10.
22. National Heart Lung and Blood Institute, National Institutes of Health. Expert panel report 3: guidelines for the diagnosis and management of asthma Washington, DC: U.S. Department of Health and Human Services. Available from: . Accessed January 29, 2014. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
23. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available from: . Accessed January 29, 2014. http://www.ginasthma.org.
24. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
25. Niven R., Chung K.F., Panahloo Z., Blogg M., Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008, 102:1371-1378.
26. Bousquet J., Siergiejko Z., Swiebocka E., Humbert M., Rabe K.F., Smith N., et al. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011, 66:671-678.
27. FitzGerald J.M., Gibson P.G. Asthma exacerbations 4: prevention. Thorax 2006, 61:992-999.
28. Gibson P.G., Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004, 59:94-99.
29. Vernon M.K., Wiklund I., Bell J.A., Dale P., Chapman K.R. What do we know about asthma triggers? A review of the literature. JAsthma 2012, 49:991-998.
30. Lehrer P.M., Isenberg S., Hochron S.M. Asthma and emotion: a review. JAsthma 1993, 30:5-21.
31. Marshall G.D. Neuroendocrine mechanisms of immune dysregulation: applications to allergy and asthma. Ann Allergy Asthma Immunol 2004, 93(Suppl 1):S11-S17.
32. Ritz T. Airway responsiveness to psychological processes in asthma and health. Front Physiol 2012, 3:343.
33. Avallone K.M., McLeish A.C., Luberto C.M., Bernstein J.A. Anxiety sensitivity, asthma control, and quality of life in adults with asthma. JAsthma 2012, 49:57-62.
34. Kurai D., Saraya T., Ishii H., Takizawa H. Virus-induced exacerbations in asthma and COPD. Front Microbiol 2013, 4:293.
35. Crocker D.D., Kinyota S., Dumitru G.G., Ligon C.B., Herman E.J., Ferdinands J.M., et al. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity: a community guide systematic review. Am J Prev Med 2011, 41:S5-S32.